Organo-ID develops patient-derived cancer organoids (PDCOs) to predict chemotherapy responses for colorectal carcinoma, utilizing advanced organoid technology to create three-dimensional in vitro disease models. This approach enables healthcare professionals to personalize cancer treatment by assessing drug effectiveness based on individual tumor characteristics.
Funding
Funding not disclosed
Founders
Product
Problem
Predicting chemotherapy responses in colorectal carcinoma (CRC) is challenging, often leading to ineffective treatments and unnecessary side effects for patients. Current methods lack the ability to accurately model individual tumor characteristics and predict drug effectiveness before administration. This uncertainty delays optimal treatment strategies and impacts patient outcomes.
Solution
Organo-ID develops patient-derived cancer organoids (PDCOs) from tumor samples to create three-dimensional in vitro models that mimic the patient's specific cancer. These PDCOs are used to predict chemotherapy responses for individual patients with colorectal carcinoma. By assessing drug effectiveness on the PDCOs, healthcare professionals can personalize cancer treatment plans. Organo-ID's technology aims to provide a reliable and personalized approach to cancer treatment by evaluating drug responses based on individual tumor characteristics before clinical administration.
Target Audience
The primary target audience includes healthcare professionals, oncologists, and researchers involved in colorectal carcinoma treatment and personalized medicine.
Features
- Development of patient-derived cancer organoids (PDCOs) from colorectal carcinoma tumor samples.
- Three-dimensional in vitro models that replicate individual tumor characteristics.
- Chemotherapy response prediction using PDCOs to assess drug effectiveness.
- Biobank of patient-derived CRC organoids for personalized drug testing.
- Exclusive licensing and commercialization rights of eHEPO technology for liver organoid production.